ZEO ScientifiX Advances to XPRIZE Healthspan Semi-Finals

ZEO ScientifiX, Inc. announced its selection as a Qualified Team for the Semi-Finals of the XPRIZE Healthspan competition. This global contest aims to revolutionize aging by developing therapeutics to restore muscle, cognitive, and immune function. ZEO, a clinical-stage biotechnology company, will now prepare its Finals Application. The company's focus is on regenerative biologics, specifically exosome therapeutics, targeting the underlying mechanisms of aging and inflammation. ZEO has assembled a multidisciplinary team of experts in clinical medicine, gene therapy, and regenerative biologics to support this endeavor. The company aims to advance its therapeutic platform through controlled clinical evaluation, generating data on safety, biological activity, and functional outcomes. This selection follows ZEO's recent appointment as the official regenerative medicine educational partner for the American Academy of Anti-Aging Medicine.